Eli Lilly has stepped up the pace of development in obesity

Eli Lilly is developing new drugs for the treatment of obesity and has a total of six projects underway, including the orforgliprone tablet and the Phase III candidate retratrutide.
Eli Lilly invests heavily in research and development in an effort to grow in the market and avoid past mistakes. | Photo: Mike Blake
Eli Lilly invests heavily in research and development in an effort to grow in the market and avoid past mistakes. | Photo: Mike Blake
by MARKETWIRE ‎

Eli Lilly has set its sights on maintaining its grip on the fast-growing market for obesity drugs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Photo: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading